Ipsos Debuts Oncology Biosimilars Syndicated Study

Ipsos Healthcare has launched a syndicated study to highlight the impact on cancer treatment of 'biosimilars' - versions of drugs created by a different manufacturer following patent expiry.

Known as the Multi-Stakeholder Biosimilar Impact Study, the new initiative will combine patient-level data from Ipsos' Global Oncology Monitor with perceptual research among doctors and payers. This, the firm says, will help subscribers gain an understanding of both physicians' intent to prescribe the drugs across the relevant oncology indications, and payers' perceptions of biosimilars, allowing forecasting of the uptake of biosimilars in each country. In addition, it will provide topological segmentation of patients based on eligibility, and analysis of physicians' awareness of different biosimilars / manufacturers and their likelihood to switch, payers' perceptions of biosimilars, and anticipated formulary / guideline placement.

Rita Caldeira, Research Director, EU Oncology Monitor, comments: 'Given the ongoing introduction of biosimilars in oncology, it is critical to understand how these products will impact current treatment practices - both for manufacturers of branded biologic products and those developing biosimilar options. The study has already generated valuable insights in the autoimmune market'.

Web site: www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Ipsos UK
• All news
• MrWeb info